Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We report two outpatients, one with schizophrenia and one with schizoaffective disorder, who developed manic or hypomanic episodes following the initiation of blonanserin during the course of treatment. Blonanserin is a novel antipsychotic that acts as a 5-HT and D2 receptor antagonist. Both patients developed hypomanic episodes within 2 weeks of receiving a small dose (6-8 mg) of blonanserin, and one patient later developed full-blown mania; both episodes ended within 1 month of discontinuing blonanserin. The mood alteration observed in these cases suggests a possible antidepressant effect of blonanserin; thus, clinicians should monitor mood changes when administering this antipsychotic.
Abstract
We report two outpatients, one with schizophrenia and one with schizoaffective disorder, who developed manic or hypomanic episodes following the initiation of blonanserin during the course of treatment. Blonanserin is a novel antipsychotic that acts as a 5-HT and D2 receptor antagonist. Both patients developed hypomanic episodes within 2 weeks of receiving a small dose (6-8 mg) of blonanserin, and one patient later developed full-blown mania; both episodes ended within 1 month of discontinuing blonanserin. The mood alteration observed in these cases suggests a possible antidepressant effect of blonanserin; thus, clinicians should monitor mood changes when administering this antipsychotic.
참고문헌 (10)
- Benyamina A, "Atypical antipsychotic-induced mania", hypomania: a review of recent case reports and clinical studies, 2012, pp.16, 2~7
- Michalopoulou PG, "Manic", hypomanic symptoms induced by atypical antipsychotics: a review of the reported cases, 2006, pp.30, 549~564
- Deeks ED, "Blonanserin: a review of its use in the management of schizophrenia", CNS Drugs, 24, pp.65~84 (2010)
- Kishi T, "Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials", J Psychiatr Res, 47, pp.149~154 (2013)
- Yang J, "Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone- compared trial", Clin Neuropharmacol, 33, pp.169~175 (2010)
- Young RC, "A rating scale for mania: reliability, validity and sensitivity", Br J Psychiatry, 133, pp.429~435 (1978)
- Rachid F, "Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases", J Clin Psychiatry, 65, pp.1537~1545 (2004)
- Ohno Y, "Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist", Pharmacol Biochem Behav, 96, pp.175~180 (2010)
- Miyamoto S, "Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs", Mol Psychiatry, 10, pp.79~104 (2005)
- Kumagai R, "Efficacy of blonanserin in combination therapy for treatment-resistant depression", Psychiatry Clin Neurosci, 63, pp.593~594 (2009)